Literature DB >> 11735652

Methods and systems to detect adverse drug reactions in hospitals.

P A Thürmann1.   

Abstract

Detection of adverse drug reactions (ADRs) in hospitals offers the chance to detect serious ADRs resulting in hospitalisation and ADRs occurring in hospitalised patients, i.e. patients with high comorbidity and receiving drugs that are administered only in hospitals. The most commonly applied methods involve stimulated spontaneous reporting of doctors and nurses, comprehensive collection by trained specialists and, more recently, computer-assisted approaches using routine data from hospital information systems. The different methods of ADR detection used result in different rates and types of ADRs and, consequently, in different drug classes being responsible for these ADRs. Another factor influencing the results of surveys is the interpretation of the term ADR, where some authors adhere to the strict definition of the World Health Organization and many others include intended and unintended poisoning as well as errors in prescribing and dispensing, thus referring to adverse drug events. Depending on the method used for screening of patients, a high number of possible ADRs and only few definite ADRs are found, or vice versa. These variations have to be taken into account when comparing the results of further analyses performed with these data. ADR rates and incidences in relation to the number of drugs prescribed or patients exposed have been calculated in only a few surveys and projects, and this interesting pharmacoepidemiological approach deserves further study. In addition, the pharmacoeconomic impact of ADRs, either resulting in hospitalisation or prolonging hospital stay, has been estimated using different approaches. However, a common standardised procedure for such calculations has not yet been defined. Although detection of ADRs in hospitals offers the opportunity to detect severe ADRs of newly approved drugs, these ADRs are still discovered by spontaneous reporting systems. The prospects offered by electronic hospital information systems as well as implementation of pharmacoepidemiological approaches increases the possibilities and the value of ADR detection in hospitals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11735652     DOI: 10.2165/00002018-200124130-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  49 in total

1.  ADE rate uncertain, reporting systems inadequate, GAO tells legislators.

Authors:  N T Landis
Journal:  Am J Health Syst Pharm       Date:  2000-03-15       Impact factor: 2.637

2.  Drug related admissions to medical wards: a population based survey.

Authors:  J Hallas; L F Gram; E Grodum; N Damsbo; K Brøsen; T Haghfelt; B Harvald; J Beck-Nielsen; J Worm; K B Jensen
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

3.  Surveillance for quality assessment: IV. Surveillance using a hospital information system.

Authors:  D C Classen; J P Burke; S L Pestotnik; R S Evans; L E Stevens
Journal:  Infect Control Hosp Epidemiol       Date:  1991-04       Impact factor: 3.254

4.  A prospective study of adverse drug reactions as a cause of admission to a paediatric hospital.

Authors:  I Martínez-Mir; M García-López; V Palop; J M Ferrer; L Estañ; E Rubio; F J Morales-Olivas
Journal:  Br J Clin Pharmacol       Date:  1996-09       Impact factor: 4.335

5.  The HELP system.

Authors:  T A Pryor; R M Gardner; P D Clayton; H R Warner
Journal:  J Med Syst       Date:  1983-04       Impact factor: 4.460

6.  Thrombotic thrombocytopenic purpura associated with clopidogrel.

Authors:  C L Bennett; J M Connors; J M Carwile; J L Moake; W R Bell; S R Tarantolo; L J McCarthy; R Sarode; A J Hatfield; M D Feldman; C J Davidson; H M Tsai
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

7.  Frequency and cost of serious adverse drug reactions in a department of general medicine.

Authors:  N Moore; D Lecointre; C Noblet; M Mabille
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 8.  The role of the clinical pharmacologist in the management of adverse drug reactions.

Authors:  N Moore
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

9.  Predisposing factors in adverse reactions to drugs.

Authors:  N Hurwitz
Journal:  Br Med J       Date:  1969-03-01

10.  Systems analysis of adverse drug events. ADE Prevention Study Group.

Authors:  L L Leape; D W Bates; D J Cullen; J Cooper; H J Demonaco; T Gallivan; R Hallisey; J Ives; N Laird; G Laffel
Journal:  JAMA       Date:  1995-07-05       Impact factor: 56.272

View more
  20 in total

1.  Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study.

Authors:  Asia N Rashed; Ian C K Wong; Noel Cranswick; Stephen Tomlin; Wolfgang Rascher; Antje Neubert
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  [Adverse drugs reactions: diagnosis and assessment].

Authors:  P A Thürmann
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

3.  Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals.

Authors:  N Tavassoli; E Duchayne; B Sadaba; K Desboeuf; A Sommet; M Lapeyre-Mestre; M J Muoz; P Sie; J Honorato; J L Montastruc; H Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2007-01-17       Impact factor: 2.953

4.  Clinical evaluation of the ADE scorecards as a decision support tool for adverse drug event analysis and medication safety management.

Authors:  Werner O Hackl; Elske Ammenwerth; Romaric Marcilly; Emmanuel Chazard; Michel Luyckx; Pascale Leurs; Regis Beuscart
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

5.  Defining 'surveillance' in drug safety.

Authors:  Jeffrey K Aronson; Manfred Hauben; Andrew Bate
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

6.  Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis.

Authors:  Irma Convertino; Stefano Salvadori; Alessandro Pecori; Maria Teresa Galiulo; Sara Ferraro; Maria Parrilli; Tiberio Corona; Giuseppe Turchetti; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

7.  Drug-related mortality among inpatients: a retrospective observational study.

Authors:  Alfredo José Pardo Cabello; Esperanza Del Pozo Gavilán; Francisco Javier Gómez Jiménez; Carmen Mota Rodríguez; Juan de Dios Luna Del Castillo; Emilio Puche Cañas
Journal:  Eur J Clin Pharmacol       Date:  2016-02-20       Impact factor: 2.953

8.  Adverse Drug Reactions in Children--International Surveillance and Evaluation (ADVISE): a multicentre cohort study.

Authors:  Asia N Rashed; Ian C K Wong; Noel Cranswick; Barbara Hefele; Stephen Tomlin; John Jackman; Kenneth Lee; Kam-Lun E Hon; Jeffrey Ong; Maisoon Ghaleb; Siew Siang Chua; Tea Ming Hui; Wolfgang Rascher; Antje Neubert
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

9.  Factors predicting hospital readmissions related to adverse drug reactions.

Authors:  Borja Ruiz; Montserrat García; Urko Aguirre; Carmelo Aguirre
Journal:  Eur J Clin Pharmacol       Date:  2008-04-03       Impact factor: 2.953

10.  Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.

Authors:  A Dugué; H Bagheri; M Lapeyre-Mestre; J F Tournamille; L Sailler; G Dedieu; R Salvayre; J P Thouvenot; P Massip; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2004-04-28       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.